Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
- change of inflammatory tear cytokine levels [ Time Frame: before treatment and after 2 months of treatment ]
Thirty microliters of phosphate-buffered saline will be injected into the inferior conjunctival sac using a micropipette. Approximately 20 μL tear fluid and buffer will be collected with a micropipette.
Cytokines are measured using the BDTM Cytometric Bead Array (CBA) (BD Bioscience, San Jose, CA). The cytokines analyzed were interleukin (IL)-1β, IL-6, IL-7, IL-8, IL-12p70, IL-17α, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and monocyte chemotactic protein-1 (MCP-1). Flow cytometry will be performed using the BDTM LSRII system (BD Bioscience, San Jose, CA).
|Study Start Date:||November 2011|
|Study Completion Date:||March 2013|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
|Experimental: Minocycline treatment group||
Drug: oral minocycline hydrochloride treatment
Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT01600625
|Korea, Republic of|
|Seoul, Korea, Republic of, 120-752|